Date published: 2026-3-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

EphA6 Inhibitors

EphA6 inhibitors represent a specialized class of chemical compounds designed to selectively target and inhibit the activity of the Ephrin type-A receptor 6 (EphA6), a member of the Eph receptor family. Eph receptors are the largest family of receptor tyrosine kinases (RTKs) and are involved in numerous cellular processes, particularly those related to cellular organization and communication. EphA6 is one of the less studied receptors within this family, but it is known to play a crucial role in the regulation of cellular architecture, particularly in the nervous system and other tissues where cell-to-cell communication is paramount. The inhibition of EphA6 disrupts its interaction with corresponding ephrin ligands, which normally leads to the activation of downstream signaling pathways that govern cellular dynamics such as adhesion, migration, and morphological changes. By blocking this receptor, EphA6 inhibitors can modulate these fundamental cellular processes, leading to altered patterns of cellular organization and movement. Structurally, EphA6 inhibitors are typically small molecules designed to interact with the ATP-binding site or other regulatory regions of the EphA6 receptor. These inhibitors are often characterized by high specificity, ensuring that they predominantly target EphA6 while minimizing off-target interactions with other Eph receptors or tyrosine kinases. The development of EphA6 inhibitors requires a deep understanding of the receptor's three-dimensional structure, particularly its active site and the conformational changes it undergoes during ligand binding and signal transduction. Advanced techniques such as X-ray crystallography, molecular docking, and computational modeling are frequently employed to design and optimize these inhibitors, ensuring they achieve the desired level of efficacy in terms of receptor binding and inhibition. As a result, EphA6 inhibitors serve as valuable tools in the study of cellular signaling pathways and the intricate mechanisms that underlie cellular organization and communication in various biological contexts.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

EGFR tyrosine kinase inhibitor, might indirectly influence signaling pathways involving EphA6.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits Bcr-Abl and other tyrosine kinases, could impact signaling related to EphA6.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-targeted receptor tyrosine kinase inhibitor, may affect pathways where EphA6 is involved.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Inhibits multiple kinases, potentially affecting signaling cascades related to EphA6.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 tyrosine kinase inhibitor, could indirectly impact EphA6 function.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR inhibitor, might influence signaling pathways involving EphA6.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially impacting EphA6-related pathways.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

Inhibits MET, VEGFR, and AXL, potentially affecting EphA6-related signaling.